Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: An interim analysis from the observational, prospective ACTION study

BMC Musculoskeletal Disorders

Volumn 16, Issue 1, 2015, Pages

  Nußlein, Hubert G ^a   Alten, Rieke ^b   Galeazzi, Mauro ^c   Lorenz, Hanns Martin ^d   Nurmohamed, Michael T ^e   Bensen, William G ^f   Burmester, Gerd R ^g   Peter, Hans Hartmut ^h   Pavelka, Karel ⁱ   Chartier, Melanie ^j   Poncet, Coralie ^k   Rauch, Christiane ^l   Le Bars, Manuela ^l  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b Schlosspark Klinik   (Germany)

^c UNIVERSITY OF SIENA   (Italy)

^d UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ST JOSEPH S HOSPITAL   (Canada)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY OF FREIBURG   (Germany)

ⁱ CHARLES UNIVERSITY   (Czech Republic)

^j Chiltern International   (France)

^k Docs International   (France)

^l BRISTOL MYERS SQUIBB   (United States)

more..

Author keywords

Abatacept; Biologic agents; Cyclic citrullinated peptide; Heart failure; Multivariate analysis; Prognostic factors; Retention; Rheumatoid arthritis

Indexed keywords

ABATACEPT; CORTICOSTEROID; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR;

ADULT; AGED; ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLUSTER ANALYSIS; COHORT ANALYSIS; COMBINATION CHEMOTHERAPY; COMORBIDITY; CONTROLLED STUDY; DATA ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG MECHANISM; DRUG RETENTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ERYTHROCYTE SEDIMENTATION RATE; EUROPE; FEMALE; GERMANY; GREECE; HAZARD RATIO; HUMAN; INFECTION; INFESTATION; INTERIM ANALYSIS; ITALY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTIVARIATE ANALYSIS; OBSERVATIONAL STUDY; POST HOC ANALYSIS; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RACE DIFFERENCE; RHEUMATOID ARTHRITIS; RISK FACTOR; TOBACCO USE; TREATMENT DURATION; TREATMENT FAILURE; UNIVARIATE ANALYSIS; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CLINICAL TRIAL; FOLLOW UP; INTERNATIONAL COOPERATION; MEDICATION COMPLIANCE; MULTICENTER STUDY;

ABATACEPT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; CANADA; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GERMANY; GREECE; HUMANS; INTERNATIONALITY; ITALY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROGNOSIS; PROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84938388159     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/s12891-015-0636-9     Document Type: Article

References (45)

1. Vicente Rabaneda EF, Herrero-Beaumont G, Castaneda S. Update on the use of abatacept for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2013;9:599-621.
2. Orencia (250 Mg Powder for Concentrate for Solution for Infusion) Summary of Product Characteristics. [http://www.medicines.org.uk/emc/medicine/19714/SPC/]
3. Orencia (125 Mg Solution for Injection) Summary of Product Characteristics. [http://www.medicines.org.uk/emc/medicine/27216/SPC/]
4. Product Monograph: Orencia (Abatacept). [http://www.bmscanada.ca/static/products/en/pm-pdf/ORENCIA-EN-PM.pdf]
5. Schiff M. Subcutaneous abatacept for the treatment of rheumatoid arthritis. Rheumatology. 2013;52:986-97.
6. Keating GM. Abatacept: a review of its use in the management of rheumatoid arthritis. Drugs. 2013;73:1095-119.
7. Nußlein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study. BMC Musculoskelet Disord. 2014;15:14.
8. Smolen JS, Landewe R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014;73:492-509.
9. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, De Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. Ann Rheum Dis. 2007;66:1473-8.
10. Daien CI, Morel J. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine. Mediators Inflamm. 2014;2014:386148.
11. Gottenberg JE, Ravaud P, Cantagrel A, Combe B, Flipo RM, Schaeverbeke T, et al. Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry. Ann Rheum Dis. 2012;71:1815-9.
12. Scarsi M, Ziglioli T. Airò P: Baseline numbers of circulating CD28-negative T cells may predict clinical response to abatacept in patients with rheumatoid arthritis. J Rheumatol. 2011;38:2105-11.
13. Saevarsdottir S, Stawiarz L, Turesson C, Linblad S. Previous biological therapies influence drug survival in rheumatoid arthritis patients starting abatacept treatment 2006-2012. Ann Rheum Dis. 2013;72:626.
14. Finckh A, Iannone F, Reino JG, Neto D, Lie E, van Riel P, et al. The impact of inadequate response to prior biologic agents on abatacept drug retention in rheumatoid arthritis patients. A pan-European analysis of RA registries. Arthritis Rheum. 2013;65:S217.
15. Nußlein H, Lorenz HM, Alten R, Bensen WG, Bessette L, Burmester G, et al. Efficacy and safety of abatacept treatment for rheumatoid arthritis (RA) in a real-life setting in European and Canadian populations: a 6-month interim analysis of the ACTION study. Ann Rheum Dis. 2011;70(Suppl3):464.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-24.
17. World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA. 1997;277:925-6.
18. Harmonised Tripartite Guideline ICH. Guideline for Good Clinical Practice. J Postgrad Med. 2001;47:199-203.
19. Stewart S, Pearce P, Florey C, Du V (Ed). Good Epidemiological Practice (GEP): IEA Guidelines for Proper Conduct in Epidemiological Research. IEA-European Federation; 2007.
20. Nußlein H, Alten R, Galeazzi M, Lorenz HM, Boumpas D, Nurmohamed MT, et al. Real-world efficacy and safety of abatacept treatment for RA: 12-month interim analysis of the ACTION study. Arthritis Rheum. 2012;64:S199.
21. World Health Organization. Global Database on Body Mass Index. http://apps.who.int/bmi/index.jsp?introPage=intro-3html& 2014
22. Leffers HC, Ostergaard M, Glintborg B, Krogh NS, Foged H, Tarp U, et al. Efficacy of abatacept and tocilizumab in patients with rheumatoid arthritis treated in clinical practice: results from the nationwide Danish DANBIO registry. Ann Rheum Dis. 2011;70:1216-22.
23. Forsblad-d'Elia H, Bengtsson K, Kristensen LE, Jacobsson LTH. Drug survival, efficacy and predictors for survival on tocilizumab in real-life patients with rheumatoid arthritis; results from the Swedish Biologics Register. Arthritis Rheum. 2012;64:S201.
24. Takeuchi T, Tanaka Y, Amano K, Hoshi D, Nawata M, Nagasawa H, et al. Clinical, radiographic and functional effectiveness of tocilizumab for rheumatoid arthritis patients - REACTION 52-week study. Rheumatology (Oxford). 2011;50:1908-15.
25. Yoshida K, Tokuda Y, Oshikawa H, Utsunomiya M, Kobayashi T, Kimura M, et al. An observational study of tocilizumab and TNF-alpha inhibitor use in a Japanese community hospital: different remission rates, similar drug survival and safety. Rheumatology (Oxford). 2011;50:2093-9.
26. Gomez-Reino JJ, Carmona L. Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period. Arthritis Res Ther. 2006;8:R29.
27. Emery P, Sebba A, Huizinga TW. Biologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritis. Ann Rheum Dis. 2013;72:1897-904.
28. Gottenberg JE, Neto D, Gomez-Reino J, Iannone F, Lie E, Canhao H, et al. Positivity for rheumatoid factor and anti-cyclic citrullinated peptide is associated with better drug retention of abatacept: data from a pan-European analysis of RA registries. Ann Rheum Dis. 2014;73(Suppl2):502.
29. Pieper J, Herrath J, Raghavan S, Muhammad K, Vollenhoven R, Malmstrom V. CTLA4-Ig (abatacept) therapy modulates T cell effector functions in autoantibody-positive rheumatoid arthritis patients. BMC Immunol. 2013;14:34.
30. Greenberg JD, Reed G, Decktor D, Harrold L, Furst D, Gibofsky A, et al. A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry. Ann Rheum Dis. 2012;71:1134-42.
31. Flipo RM, Sibilia J, Westhovens R, Gaillez C, Le Bars M, Poncet C, et al. Treatment with abatacept plus DMARDs over 6 months in the ATTAIN study: results show similar efficacy benefits in patients who exeriece primary versus secondary failure of prior anri-TNF therapy. Rev Rhum. 2011;78:A302.
32. Weinblatt ME, Moreland LW, Westhovens R, Cohen RB, Kelly SM, Khan N, et al. Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical trial program. J Rheumatol. 2013;40:787-97.
33. Golimumab Summary of Product Characteristics. [http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000992/WC500052368.pdf]
34. Certolizumab Pegol Summary of Product Characteristics. [http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/001037/WC500069763.pdf]
35. Adalimumab Summary of Product Characteristics. [http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000481/WC500050870.pdf]
36. Infliximab Prescribing Information. [http://www.remicade.com/remicade/assets/hcp-ppi.pdf]
37. Etanercept Summary of Product Characteristics. [http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Product-Information/human/000262/WC500027361.pdf]
38. Finckh A, Neto D, Iannone F, Loza E, Lie E, van Riel P, Hetland ML, et al. The impact of patient heterogeneity and socio-economic factors on abatacept retention in rheumatoid arthritis across nine European countries. RMD open 2015, in press.
39. Neto D, Finckh A, Iannone F, Loza E, Lie E, Van Riel PLC, et al. Differences in abatacept use in rheumatoid arthritis patients across Europe: a pan-European database analysis of abatacept in European RA registries. Arthritis Rheum. 2013;65:S1248.
40. Pedersen JK, Kjaer NK, Svendsen AJ, Horslev-Petersen K. Incidence of rheumatoid arthritis from 1995 to 2001: impact of ascertainment from multiple sources. Rheumatol Int. 2009;29:411-5.
41. Carbonell J, Cobo T, Balsa A, Descalzo MA, Carmona L. The incidence of rheumatoid arthritis in Spain: results from a nationwide primary care registry. Rheumatology (Oxford). 2008;47:1088-92.
42. Miltenburger C, Gunther OH, Justo N, Karampampa K, Texier-Richard B, Schweikert B. A Survey of Barriers to Treatment Access in Rheumatoid Arthritis in France, Germany, Italy, Spain and the UK [http://www.comparatorreports.se/RA%20Barrier%20Report-FINAL-050110.pdf]
43. Kobelt G and Kasteng. Access to Innovative Treatments in Rheumatoid Arthritis in Europe [http://www.lif.se/default.aspx?id=44400]
44. Hockley T and Costa-Font J. A Common Disease With Uncommon Treatment. European Guideline Variations and Access to Innovative Therapies for Rheumatoid Arthritis. [http://www.policy-centre.com/downloads/Guideline-Variations-Report-2012-Final.pdf]
45. Lindblad S, Stawiarz L. Gender and previous treatment influence outcomes from abatacept in a 5-year rheumatoid arthritis cohort. Ann Rheum Dis. 2012;71:383.